Ildong Pharmaceutical is showing strength. The news that its dedicated research and development (R&D) subsidiary YUNOVIA has officially launched appears to be influencing the stock price.
As of 2:52 PM on the 2nd, Ildong Pharmaceutical is trading at 16,310 KRW, up 5.84% from the previous day.
YUNOVIA continues business activities based on the R&D assets and new drug pipelines held by Ildong Pharmaceutical. It has secured 6 to 7 new drug pipelines in the fields of metabolic diseases, degenerative diseases, liver diseases, gastrointestinal diseases, and ophthalmic diseases. Additionally, by adding cancer, cardiovascular diseases, neuropsychiatric diseases, infectious diseases, and pulmonary/respiratory disease new drug research projects, platform technologies, and microbiome projects, it currently holds about 25 pipelines.
Development is focused on the metabolic disease new drug candidate 'ID110521156' targeting type 2 diabetes and obesity, and the Parkinson's disease treatment candidate 'ID119040338'. The company explained that the metabolic disease new drug candidate 'ID110521156', a GLP-1 receptor agonist targeting type 2 diabetes and obesity, and the A1·A2A receptor antagonist 'ID119040338', being developed as a treatment for Parkinson's disease, a degenerative disease, are attracting interest from numerous global companies.
A YUNOVIA official stated, "We will establish ourselves as an R&D specialized company with a sustainable virtuous cycle structure by leading with competitive and promising pipelines."
Dalmi Lee, a researcher at the Korea IR Association, explained, "For companies like Hanmi Pharmaceutical, Yuhan Corporation, and Chong Kun Dang, whose market capitalization exceeds trillions of won, R&D achievements have led to increases in corporate value through license-outs or positive clinical data outcomes."
She added, "Ildong Pharmaceutical's corporate value has not yet reflected expectations for R&D, so its valuation attractiveness is considered high. If results are produced for the most anticipated diabetes treatment candidate ID110521156, the corporate value will level up."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
